Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils

Clinical and Diagnostic Laboratory Immunology

Volumn 6, Issue 3, 1999, Pages 420-424

  Åhlin, Anders ^a,b   Lärfars, Gerd ^b   Elinder, Göran ^a,b   Palmblad, Jan ^b   Gyllenhammar, Hans ^b  

^a SACHS CHILDREN S HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; GAMMA INTERFERON; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; FEMALE; HOST RESISTANCE; HUMAN; MALE; NEUTROPHIL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0344299207     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/cdli.6.3.420-424.1999     Document Type: Article

References (31)

1. Åhlin, A., M. de Boer, D. Roos, J. Leusen, C. I. E. Smith, U. Sundin, H. Rabbani, J. Palmblad, and G. Elinder. 1995. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr. 84:1386-1394.
2. Åhlin, A., G. Elinder, and J. Palmblad. 1997. Dose dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 89:3396-3401.
3. Beckman, J. S., T. W. Beckman, J. Chen, P. A. Marshall, and B. A. Freeman. 1990. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA 87:1620-1626.
4. Boockvar, K. S., D. L. Granger, R. M. Poston, M. Maybodi, M. K. Washington, J. B. Hibbs, Jr., and R. L. Kurlander. 1994. Nitric oxide produced during murine listeriosis is protective. Infect. Immun. 62:1089-1100.
5. Bratt, J., and H. Gyllenhammar. 1995. The role for nitric oxide in lipoxin A4-induced polymorphonuclear neutrophil-dependent cytotoxicity towards human vascular endothelium, in vitro. Arthritis Rheum. 38:768-776.
6. Bryant, J. L., P. Mehta, A. Vonderporten, and J. L. Mehta. 1992. Co-purification of 130 kd nitric oxide synthase and a 22 kd link protein from human neutrophils. Biochem. Biophys. Res. Commun. 189:558-563.
7. Condino-Neto, A., M. N. Muscara, A. S. Grumach, M. M. S. Carneiro-Sampaio, and G. De Nucci. 1993. Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide. Br. J. Clin. Pharmacol. 35:485-490.
8. Condino-Neto, A., M. Muscara, R. Bellinati-Pires, M. M. Carneiro-Sampaio, A. C. Brandao, A. S. Grumach, and G. De Nucci. 1996. Effect of therapy with recombinant human interferon-gamma on the release of nitric oxide by neutrophils and mononuclear cells from patients with chronic granulomatous disease. J. Interferon Cytokine Res. 16:357-364.
9. Cross, A. S., W. Zollinger, R. Manrell, P. Gemski, and J. Sadoff. 1983. Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by K1-positive Escherichia coli. J. Infect. Dis. 147:68-76.
10. Ezekowitz, R. A. B., S. H. Orkin, and P. E. Newburger. 1987. Recombinant Interferon gamma augments phagocyte superoxide production and chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J. Clin. Investig. 80:1009-1016.
11. Ezekowitz, R. A. B., M. C. Dinauer, H. S. Jaffe, H. O. Stuart, and P. E. Newburger. 1988. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N. Engl. J. Med. 319:146-151.
12. Feelisch, M., and E. A. Noack. 1987. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol. 139:19-30.
13. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon-gamma in resistance to mycobacterium-tuberculosis infection. J. Exp. Med. 178:2249-2254.
14. Gorbunov, N., and E. Esposito. 1993. Nitric oxide as a mediator of inflammation. Int. J. Immunopathol. Pharmacol. 6:67-76.
15. Gyllenhammar, H. 1987. Lucigenin chemiluminescence in the assessment of neutrophil superoxide production. J. Immunol. Methods 97:209-215.
16. Huizinga, T. W., C. E. van der Schoot, D. Roos, and R. Weening. 1991. Induction of neutrophil Fc-gamma receptor expression can be used as a marker for biologic activity of recombinant interferon-gamma in vivo. Eur. J. Clin. Investig. 21:48-50.
17. International Chronic Granulomatous Disease Cooperative Study Group. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N. Engl. J. Med. 324:509-516.
18. Klebanoff, S. J., and C. F. Nathan. 1993. Nitrite production by stimulated human polymorphonuclear leukocytes supplemented with azide and catalase. Biochem. Biophys. Res. Commun. 197:192-198.
19. Lantoine, F., S. Trevin, F. Bedioui, and J. Devynck. 1995. Selective and sensitive electrochemical measurement of nitric oxide in aqueous solution: discussion and new results. J. Electroanal. Chem. 392:85-93.
20. 2+ concentration. Biochem. Biophys. Res. Commun. 215:842-849.
21. Lärfars, G., and H. Gyllenhammar. 1995. Measurement of methemoglobin formation from oxyhemoglobin. A real-time, continuous assay of nitric oxide release by human polymorphonuclear leukocytes. J. Immunol. Methods 184: 53-62.
22. Malawista, S. E., R. R. Montgomery, and B. G. van Blaricom. 1992. Evidence for reactive nitrogen intermediates in killing of staphylococci by human neutrophil cytoplasts. A new microbicidal pathway for polymorphonuclear leukocytes. J. Clin. Investig. 90:631-636.
23. Meerhof, L. J., and D. Roos. 1986. Heterogeneity in chronic granulomatous disease detected with an improved nitroblue tetrazolium slide test. J. Leukoc. Biol. 39:699-711.
24. Moncada, S., and E. A. Higgs. 1991. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Investig. 21:361-371.
25. 558 content or levels of four anti-microbial proteins. Clin. Exp. Immunol. 88:203-206.
26. Rex, J. H., J. E. Bennett, J. I. Gallin, H. L. Malech, and E. S. DeCarlo. 1991. In vivo interferon-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J. Infect. Dis. 163:849-852.
27. Thrasher, A. J., N. H. Keep, F. Wientjes, and A. Segal. 1994. Chronic granulomatous disease. Biochim. Biophys. Acta 1227:1-24.
28. Weening, R. S., G. J. Leitz, and R. A. Seger. 1995. Recombinant human interferon-gamma in patients with chronic granulomatous disease - European follow up study. Eur. J. Pediatr. 154:295-298.
29. Wheeler, M. A., S. D. Smith, G. Garcia-Cardena, C. F. Nathan, R. M. Weiss, and W. M. Sessa. 1997. Bacterial infection induces nitric oxide synthase in human neutrophils. J. Clin. Investig. 99:110-116.
30. Woodman, R. C., R. W. Erickson, J. Rae, H. S. Jaffe, and J. T. Curnutte. 1992. Prolonged recombinant Interferon-γ therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 79: 1558-1562.
31. Wright, C. D., A. Muelsh, R. Busse, and H. Osswald. 1989. Generation of nitric oxide by human neutrophils. Biochem. Biophys. Res. Commun. 160: 813-819.